Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;103(6):323-330.
doi: 10.4174/astr.2022.103.6.323. Epub 2022 Dec 8.

Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant

Yoon Ju Bang  1 , Won Kyung Kwon  2 , Jong-Won Kim  2 , Jeong Eon Lee  3 , Boo Yeon Jung  4 , Mina Kim  4 , Jisun Kim  5 , Jeongshin An  6 , Seung Pil Jung  7 , Hong-Kyu Kim  8 , Zisun Kim  9 , Hyun Jo Youn  10 , Jai Min Ryu  3 , Sung-Won Kim  11 ; Korean Hereditary Breast Cancer Study Group
Affiliations

Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant

Yoon Ju Bang et al. Ann Surg Treat Res. 2022 Dec.

Abstract

Purpose: We provide evidence for the reclassification of the BRCA1:c.5017_5019del variant by presenting the clinicopathological characteristics, clinical outcomes, and family history of breast or ovarian cancer in 17 patients with this variant.

Methods: This study included breast or ovarian cancer patients tested for BRCA1/2 genes between January 2008 and June 2020 at 10 medical centers in Korea. We retrospectively reviewed 17 probands from 15 families who had the BRCA1:c.5017_5019del variant according to the electronic medical records.

Results: We present 10 breast cancer patients and 7 ovarian cancer patients from 15 families identified as having BRCA1:c.5017_5019del and a total of 19 cases of breast cancer and 14 cases of ovarian cancer in these families. The ratio of breast-to-ovarian cancer was 1.3:1. Breast cancer patients with this variant showed a rich family history of breast or ovarian cancer, 8 patients (80.0%). The mean age at diagnosis was 45.4 years and 6 patients (60.0%) were categorized into hormone-receptor-negative breast cancer. Also, the ovarian cancer patients with this variant showed strong family histories of breast and/or ovarian cancer in 4 patients (57.1%).

Conclusion: We presented clinical evidence for the reclassification of BRCA1:c.5017_5019del as a likely pathogenic variant (LPV). Reclassification as LPV could result in the prophylactic treatment and medical surveillance of probands, family testing recommendations, and appropriate genetic counseling of their families.

Keywords: BRCA1; Breast neoplasms; Genes; Genetic testing; Hereditary breast and ovarian cancer syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Pedigree of family B.
Fig. 2
Fig. 2. Chromatogram of Sanger sequencing of BRCA1: c.5017_5019del.
See this image and copyright information in PMC

References

    1. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 2002;8:571–576. - PubMed
    1. Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, et al. BRCA genes: BRCA 1 and BRCA 2. J BUON. 2018;23:862–866. - PubMed
    1. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39:593–620. - PMC - PubMed
    1. Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7:230–237. - PMC - PubMed
    1. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77–102. - PubMed